The Evolving Treatment Paradigm of Hepatocellular Carcinoma: An Expert Case-based Discussion

Centering discussion on clinical trial data and real-world patient profiles, expert oncologists review the treatment paradigm for hepatocellular carcinoma and consider how they would sequence therapy.

EP. 1: Early- and Intermediate-Stage HCC Treatment Landscape

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.

EP. 2: Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

EP. 3: Role of Systemic Therapy in Early- or Intermediate-Stage HCC

October 7th 2022

Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.

EP. 4: Advanced HCC: Updates in First-line Systemic Therapy

October 7th 2022

Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.

EP. 5: Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

October 14th 2022

Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.

EP. 6: Selecting the Appropriate First-Line Therapy for Advanced HCC

October 14th 2022

In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.

EP. 7: Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

October 21st 2022

Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.

EP. 8: Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

October 21st 2022

Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.

EP. 9: Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

October 28th 2022

Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.

EP. 10: Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

October 28th 2022

In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.

EP. 11: Novel First-Line Immunotherapy Approaches in Advanced HCC

November 4th 2022

Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.

EP. 12: Treatment Options for Advanced HCC in the Second-Line and Beyond

November 4th 2022

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

EP. 13: Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

November 11th 2022

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

EP. 14: Management of Hepatocellular Carcinoma: Future Directions in Care

November 11th 2022

Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.